Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.

about

Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections.

Item

http://www.wikidata.org/entity/Q50271090

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Biological evaluation of diphe ...... lous mycobacterial infections.

@en

Biological evaluation of diphenyleneiodonium chloride

@nl

type

Item

label

Biological evaluation of diphe ...... lous mycobacterial infections.

@en

Biological evaluation of diphenyleneiodonium chloride

@nl

prefLabel

Biological evaluation of diphe ...... lous mycobacterial infections.

@en

Biological evaluation of diphenyleneiodonium chloride

@nl

P1476

Biological evaluation of diphe ...... lous mycobacterial infections.

@en

P2093

Alok Kumar Singh

http://www.w3.org/2001/XMLSchema#string

Amit Kumar Pandey

http://www.w3.org/2001/XMLSchema#string

Arunava Dasgupta

http://www.w3.org/2001/XMLSchema#string

Isha Soni

http://www.w3.org/2001/XMLSchema#string

Manitosh Pandey

http://www.w3.org/2001/XMLSchema#string

Pratiksha Karaulia

http://www.w3.org/2001/XMLSchema#string

Ritesh Thakare

http://www.w3.org/2001/XMLSchema#string

Sidharth Chopra

http://www.w3.org/2001/XMLSchema#string

Swetarka Das

http://www.w3.org/2001/XMLSchema#string

P2860

Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger?

Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors.

A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Mycobacterium abscessus: a new antibiotic nightmare.

Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.

Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria.

Lack of antimicrobial bactericidal activity in Mycobacterium abscessus.

Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others

Prevalence and drug resistance of nontuberculous mycobacteria, northern China, 2008-2011.

GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus.

P304

3117-3121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKX277

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28961864

http://www.w3.org/2001/XMLSchema#string